

Date: May 02, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with sub-para 20 of Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Senores Pharmaceuticals Inc., Wholly Owned Subsidiary of the Company (“SPI”) has received a notice from Department of the Treasury Internal Revenue Service, Ogden, UT 84201-0039, imposing the penalty and interest due to alleged non-payment of tax.

SPI believes that since the said tax has already been paid there is no case of imposing of penalty.

The details as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular dated November 11, 2024, are enclosed herewith as **Annexure-1** for your reference.

We request you to take the above information on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Annexure - 1
Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Description
1.	Name of Authority	Department of the Treasury Internal Revenue Service, Ogden, UT 84201-0039 ("IRS").
2.	Nature and details of the action(s) taken, initiated or order(s) passed	Penalty and Interest on alleged non-payment of tax imposed by IRS on Senores Pharmaceuticals Inc., Wholly Owned Subsidiary of the Company ("SPI").
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Notice dated April 21, 2025, received on May 01, 2025.
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Due to alleged non-payment of tax by SPI to IRS, a penalty of USD 22,981.20 and interest charges of USD 27,554.34 have been imposed on SPI.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on financials, operations or other activities of the Company and SPI due to the said notice. SPI believes that since the said tax has already been paid there is no case of imposing of penalty. SPI is in process of taking up the matter with IRS for necessary corrections.

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263